Anti-hepatitis B virus activity and mechanisms of recombinant human serum albumin-interferon-α-2b fusion protein in vitro and in vivo

Pharmacology

Volumn 83, Issue 6, 2009, Pages 323-332

  Bingfa, Xu ^a   Qinglin, Fan ^a   Hui, Huang ^a   Canjun, Wang ^a   Wei, Wei ^a   Lihua, Song ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

2 ,5 Oligoadenylate synthetase; Duck hepatitis B virus; Hepatitis B virus; HepG2 2.2.15; Recombinant human serum albumin interferon 2b fusion protein

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; 2',5' OLIGOADENYLATE SYNTHETASE 1; ALANINE AMINOTRANSFERASE; BILIRUBIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON STIMULATED GENE FACTOR 3; RECOMBINANT ALBUMIN; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT PROTEIN; STAT1 PROTEIN; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DUCK; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VIRUS REPLICATION; WESTERN BLOTTING;

2',5'-OLIGOADENYLATE SYNTHETASE; ALANINE TRANSAMINASE; ANIMALS; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; CELL LINE; DNA; DNA, VIRAL; DRUG EVALUATION, PRECLINICAL; DUCKS; HEPATITIS B VIRUS; HEPATITIS B VIRUS, DUCK; HUMANS; INTERFERON ALFA-2B; INTERFERON-STIMULATED GENE FACTOR 3; LIVER; RANDOM ALLOCATION; RECOMBINANT FUSION PROTEINS; STAT1 TRANSCRIPTION FACTOR; UP-REGULATION; VIRUS REPLICATION;

EID: 65449185919     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000215588     Document Type: Article

References (30)

1. Hayashi PH, Di Bisceglie AM: The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: epidemiology and pathogenesis. Med Clin North Am 2005; 89:371-389.
2. Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11:97-107.
3. Hu KQ: Hepatitis B virus (HBV) infection in Asian and Pacific Islander Americans (APIAs): how can we do better for this special population? Am J Gastroenterol 2008; 103:1824-1833.
4. Korba BE, Milman G: A cell culture assay for compounds which inhibit hepatitis B virus replication. Antiviral Res 1991; 15: 217-228.
5. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, et al: Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10: 298-305.
6. Saxena S, Nouri-Aria KT, Anderson MG, Williams R, Eddleston AL: In vitro alpha-interferon treatment of peripheral blood mononuclear cells improves interleukin-2 activity in HBV-related chronic liver disease. J Hepatol 1985; 1:385-393.
7. Barone AA, de Paula Cavalheiro N, Suemat-su S: Response in patients with chronic HCV hepatitis to treatment with interferon-alpha. Braz J Infect Dis 1999; 3:118-128.
8. Liu C, Zhu H, Subramanian GM, Moore PA, Xu Y, Nelson DR: Anti-hepatitis C virus activity of albinterferon alfa-2b in cell culture. Hepatol Res 2007; 37:941-947.
9. Malathi K, Paranjape JM, Bulanova E, Shim M, Guenther-Johnson JM, Faber PW, et al: A transcriptional signaling pathway in the IFN system mediated by 2′,5′-oligoadenylate activation of RNase L. Proc Natl Acad Sci USA 2005; 102: 14533-14538.
10. Sells MA, Chen ML, Acs G: Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA 1987; 84: 1005-1009.
11. Sells MA, Zelent AZ, Shvartsman M, Acs G: Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. J Virol 1988; 62:2836-2844.
12. Zoulim F, Trepo C: New antiviral agents for the therapy of chronic hepatitis B virus infection. Intervirology 1999; 42:125-144.
13. Mason WS, Seal G, Summers J: Virus of Pe-kin ducks with structural and biological re-latedness to human hepatitis B virus. J Virol 1980; 36:829-836.
14. Hayashi Y, Koike K: Interferon inhibits hepatitis B virus replication in a stable expression system of transfected viral DNA. J Virol 1989; 63: 2936 -2940.
15. Shin MS, Kang EH, Lee YI: A flavonoid from medicinal plants blocks hepatitis B virus-e antigen secretion in HBV-infected hepatocytes. Antiviral Res 2005; 67:163-168.
16. Guo Q, Zhao L, You Q, Yang Y, Gu H, Song G, et al: Anti-hepatitis B virus activity of wogonin in vitro and in vivo. Antiviral Res 2007; 74: 16-24.
17. Goh KC, Haque SJ, Williams BR: p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J 1999; 18: 5601-5608.
18. Desmet VJ, Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, et al: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis [He-patology 1981; 1: 431-435]. J Hepatol 2003; 38: 382-386.
19. Ikawa H, Hayashi Y, Ninomiya T, Yano Y, Nakaji M, Nagano H, et al: Various scoring systems evaluating histologic features of chronic hepatitis C treated with interferon. Hum Pathol 2001; 32:910-917.
20. Craxi A, Di Bona D, Camma C: Interferon-alpha for HBeAg-positive chronic hepatitis B. J Hepatol 2003; 39(suppl 1):S99-S105.
21. Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A, et al: Pharmacoki-netic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 2002; 303:540-548.
22. Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, et al: Early mono-therapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 2006; 43: 250-256.
23. Bain VG, Kaita KD, Yoshida EM, Swain MG, Heathcote EJ, Neumann AU, et al: A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 20 06; 44: 671-678.
24. Subramanian GM, Fiscella M, Lamouse-Smith A, Zeuzem S, McHutchison JG: Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol 2007; 25:1411-1419.
25. Zeuzem S, Yoshida EM, Benhamou Y, Pian-ko S, Bain VG, Shoual D, et al: Albinterferon alfa-2b dosed every two or four weeks in in-terferon-naive patients with genotype 1 chronic hepatitis C. Hepatology 2008; 48: 407-417.
26. Brierley MM, Fish EN: Stats: multifaceted regulators of transcription. J Interferon Cytokine Res 2005; 25:733-744.
27. Ren FY, Jin H, Piao XX, Piao FS: Ribavirin and IFN-alpha combination therapy induces CD4+ T-cell proliferation and Th1 cytokine secretion in patients with chronic hepatitis B. World J Gastroenterol 2007; 13:5440-5445.
28. Nakao K, Nakata K, Yamashita M, Tamada Y, Hamasaki K, Ishikawa H, et al: p48 (ISGF-37) is involved in interferon-α-induced suppression of hepatitis B virus enhancer-1 activity. J Biol Chem 1999; 274: 28075-28078.
29. Zhang Q, Wang Y, Wei L, Jiang D, Wang JH Rao HY, et al: Role of ISGF3 in modulating the anti-hepatitis B virus activity of interfer-on-α in vitro. J Gastroenterol Hepatol 2007; 11:1747-1761.
30. Huang YS, Chen Z, Yang ZY, Wang TY, Zhou L, Wu JB, et al: Preparation and characterization of a potent, long-lasting recombinant human serum albumin-interferon-alpha2b fusion protein expressed in Pichia pastoris. Eur J Pharm Biopharm 2007; 67:301-308.